Phase II Study of Weekly Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 7 (2) , 141-145
- https://doi.org/10.3816/cbc.2006.n.023
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast CancerClinical Breast Cancer, 2004
- A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancerAnnals of Oncology, 2004
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human MalignanciesJournal of Clinical Oncology, 2002
- Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II TrialJournal of Clinical Oncology, 2001
- Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient TherapyThe Oncologist, 2001
- A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 2000
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989